Nephro-Urology Monthly

Published by: Kowsar

No Association Between Cyclosporine Levels and Dyslipidemia?

Guido Filler 1 , 2 , 3 , *
Author Information
1 Department of Pathology and Laboratory Medicine, University of Western Ontario, Ontario, Canada
2 Department of Pediatrics, University of Western Ontario, Ontario, Canada
3 Department of Medicine, University of Western Ontario, Ontario, Canada
Article information
  • Nephro-Urology Monthly: January 01, 2014, 6 (1); e14296
  • Published Online: January 13, 2014
  • Article Type: Letter
  • Received: August 19, 2013
  • Accepted: December 1, 2013
  • DOI: 10.5812/numonthly.14296

To Cite: Filler G. No Association Between Cyclosporine Levels and Dyslipidemia?, Nephro-Urol Mon. 2014 ; 6(1):e14296. doi: 10.5812/numonthly.14296.

Copyright © 2014, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnote
References
  • 1. Hosseini M, Rostami Z, Einollahi B. Dyslipidemia After Kidney Transplantation and Correlation With Cyclosporine Level. Nephr Urol Mon. 2013; 5(3): 831-4[DOI]
  • 2. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Ame J Kidney Dis. 1998; 32(5): 853-906[PubMed]
  • 3. Filler G. Challenges in pediatric transplantation: the impact of chronic kidney disease and cardiovascular risk factors on long-term outcomes and recommended management strategies. Pediatr Transplant. 2011; 15(1): 25-31[DOI][PubMed]
  • 4. Zhang Y, Zhang XD, Wang Y. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study. Transplant Proc. 2011; 43(10): 3697-701[DOI][PubMed]
  • 5. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008; 14(4): 512-25[DOI][PubMed]
  • 6. Feber J, Wong H, Geier P, Chaudry B, Filler G. Complications of chronic kidney disease in children post-renal transplantation - a single center experience. Pediatr Transplant. 2008; 12(1): 80-4[DOI][PubMed]
  • 7. Akbari A, Hussain N, Karpinski J, Knoll GA. Chronic kidney disease management: comparison between renal transplant recipients and nontransplant patients with chronic kidney disease. Nephron Clin Pract. 2007; 107(1)-13[DOI][PubMed]
  • 8. Filler G, Lipshultz SE. Why multidisciplinary clinics should be the standard for treating chronic kidney disease. Pediatr Nephrol. 2012; 27(10): 1831-4[DOI][PubMed]
  • 9. Sciarretta S, Valenti V, Tocci G, Pontremoli R, Rosei EA, Ambrosioni E, et al. Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy - Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens. 2010; 28(2): 251-8[DOI][PubMed]
  • 10. Filler G, Weiglein G, Gharib MT, Casier S. Omega3 fatty acids may reduce hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant. 2012; 16(8): 835-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments